Endometriosis Treatments Market Size Is Projected To Reach USD 6.53 Billion By 2035 SNS Insider

The U.S. Endometriosis Treatment Market was valued at USD 0.89 billion in 2025 and is expected to reach USD 2.71 billion by 2035, growing at a CAGR of 11.9% during 2026–2035. The U.S. continues to hold a leading position in the global endometriosis treatment market, supported by advanced healthcare infrastructure, high awareness levels, and strong investment in women's health research.

Rising Disease Awareness and Increasing Diagnosis Rates to Propel Market Expansion Globally

The market's growth trajectory is mostly being driven by increased awareness of endometriosis as a chronic gynecological ailment, enhanced diagnostic capabilities, and expanded screening programs. The long-standing problem of underdiagnosis is being lessened by increased educational initiatives by advocacy groups and healthcare professionals, which promote early diagnosis and prompt intervention. Furthermore, improvements in minimally invasive diagnostic techniques and imaging technologies are improving detection accuracy, which increases the number of patients who can receive therapy. The demand for endometriosis treatments in hospital, specialized clinic, and outpatient care settings is gradually increasing due to these reasons taken together, promoting long-term global market expansion.

Major Endometriosis Treatments Companies SWOT Analysis Listed in the Report are

• AbbVie Inc.
• Pfizer Inc.
• Bayer AG
• Takeda Pharmaceutical Company Limited
• Novartis AG
• AstraZeneca plc
• Ferring Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• ObsEva SA
• Theramex
• Mylan N.V.
• Amgen Inc.
• Sanofi S.A.
• Gedeon Richter Plc.
• Lupin Limited
• Zydus Lifesciences Ltd.
• Dr. Reddy's Laboratories Ltd.
• Sun Pharmaceutical Industries Ltd.

Endometriosis Treatments Market Segmentation Analysis:

By Type

The hormone therapy segment captured the highest revenue share of approximately 77.9% in 2025, primarily driven by its widespread clinical use in managing endometriosis symptoms through hormonal regulation and suppression of estrogen production. The pain medication segment accounted for a smaller share of 22.1% in 2025 and is projected to grow at a CAGR of 9.6% during 2026 to 2035, supported by continued reliance on NSAIDs and analgesics for symptomatic relief globally.

By Drug Class

The gonadotropin-releasing hormone segment held the leading share of approximately 50.0% in 2025, supported by its effectiveness in suppressing ovarian hormone production globally. Oral contraceptives accounted for around 28.5% of the market and are expected to grow at a CAGR of 11.1% over the forecast period, driven by their accessibility, affordability, and widespread use in early-stage disease management globally.

By Route of Administration

The oral route of administration dominated the market with a share of approximately 49.1% in 2025 due to patient preference for convenient, non-invasive treatment options and the widespread availability of oral hormonal therapies and pain medications globally. The injectable segment accounted for 30.8% of the market and is expected to grow at a CAGR of 12.2% during 2026 to 2035, driven by increasing adoption of long-acting hormone therapies that offer improved compliance and sustained therapeutic effects globally.

By Distribution Channel

Retail pharmacies held the largest share of approximately 52.3% in 2025 due to their extensive reach, ease of access, and growing role in chronic disease medication dispensing globally. Hospital pharmacies accounted for 29.9% of the market, benefiting from direct physician prescriptions and the management of more complex or severe cases within clinical settings globally.